Navigation Links
JCI early table of contents for Feb. 8, 2013

Rooting out recurrent breast cancer

Due to chemotherapy resistance and a high rate of relapse, triple negative cancers are among the most difficult breast cancers to treat. In this issue of the Journal of Clinical Investigation, researchers led by Carlos Arteaga at Vanderbilt University identified a protein, TGF-β, that is highly expressed in triple negative breast cancer cells after chemotherapy. In a mouse model of breast cancer, TGF-β both diverted cells down a path to becoming cancerous and allowed for cancer to come back after treatment. Importantly, loss of TGF-β prevented tumor recurrence in mice. These studies identify a mechanism by which cancer cells elude standard chemotherapy and provide a rationale for testing the therapeutic potential of agents that block TGF-β.

TGFβ inhibition enhances chemotherapy action against triple negative breast cancer

Carlos Arteaga
Vanderbilt University, Nashville, TN, USA
Phone: 615-936-3524; Fax: 615-936-1790; E-mail:

View this article at:

Targeting T cells in rheumatoid arthritis

Rheumatoid arthritis (RA) is an autoimmune disorder in which immune cells attack the joints, causing inflammation, swelling, and erosion. Specific sets of immune cells, known as T cells, are responsible for inducing disease. In this issue of the Journal of Clinical Investigation, researchers led by Harvey Cantor at Harvard University analyzed the contributions of different subsets of T cells to an RA-like condition in mice. Cantor and colleagues identified a subset of regulatory T cells (CD8+ Tregs) that can remove pathogenic T cell subsets and inhibit disease progression. Additionally, they identified small proteins that induced more CD8+ Tregs. These findings suggest that enhancing specific T cell subsets may be useful in combating RA and other autoimmune diseases.


Amelioration of arthritis through mobilization of peptide-specific CD8+ regulatory T-cells

Harvey Cantor
Dana Farber Cancer Institute, Boston, MA, USA
Phone: 617-632-3348; Fax: 617-632-4630; E-mail:

View this article at:

New insight into RASopathy-associated lymphatic defects

The RAS pathway is a cellular signaling pathway that regulates growth and development in humans. RASopathies are a group of diseases characterized by defects in RAS signaling. Many patients with RASopathies present with defects in the lymphatic system, which removes excess fluid from tissues, absorbs fats from the digestive system, and transports immune cells. To determine how alterations in the RAS pathway affect development of the lymphatic system, researchers at Yale University generated transgenic mice that expressed mutations associated with a RASopathy known as Noonan syndrome. In this issue of the Journal of Clinical Investigation, Michael Simon and colleagues report that excess RAS pathway activation triggers increased activity of a protein known as ERK. Mice with RASopathy-associated mutations exhibited lymphatic defects similar to those seen in humans, but the defects could be reversed by treatment with an ERK inhibitor. These findings demonstrate that excessive ERK activation underlies lymphatic defects in RASopathies and suggest that ERK inhibition could be a useful therapeutic strategy.

Endothelial ERK signaling controls lymphatic fate specification

Michael Simons
Yale University School of Medicine, New Haven, CT, USA
Phone: 203-785-7000; Fax: 203-785-7144; E-mail:

View this article at:


Modified Foxp3 mRNA protects against asthma through an IL-10-dependent mechanism

Michael Kormann
University of Tbingen, Tbingen, DEU
Phone: 49-707-129-84305; Fax: 49-70-712-94717; E-mail:

View this article at:

CXCL5 limits macrophage foam cell formation in atherosclerosis

Johan Duchene
Max Delbrck Center for Molecular Medicine, Berlin, DEU
Phone: +49 (0)30 9406-3592; E-mail:

View this article at:

SHP-1 phosphatase activity counteracts increased T cell receptor affinity

Nathalie Rufer
University of Lausanne, Lausanne, UNK, CHE
Phone: +41 21 314 01 99; Fax: +41 21 314 74 77; E-mail:

View this article at:

PAR-1 contributes to the innate immune response during viral infection

Nigel Mackman
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Phone: 919 843 3961; Fax: 919 843 4896; E-mail:

View this article at:

Muscle lipogenesis balances insulin sensitivity and strength through calcium signaling

Clay F. Semenkovich
Washington University, St. Louis, MO, USA
Phone: 314-362-4454; E-mail:

View this article at:


Contact: Jillian Hurst
Journal of Clinical Investigation

Related medicine news :

1. Students in Educational First Steps Assisted Centers Show Persistent Benefits Far Beyond Early Childhood According to University of Texas at Dallas Study
2. Exposure to Smog in Early Pregnancy Linked to Complications
3. Mayo Clinic-led study identifies biomarkers for early risk assessment of acute kidney injury
4. Mammogram every 2 years has same benefit as yearly mammogram for older women, UCSF study finds
5. Early breast cancer diagnosis, survival rates low in rural India
6. JCI early table of contents for Feb. 1, 2013
7. Bioelectric signals can be used to detect early cancer
8. Blacks Less Likely to Receive Kidney Transplant Early On, Study Finds
9. Belly Fat May Raise Odds of Early Death for Thin Heart Patients
10. Sugar Addict Claims Americans Consuming 150 lbs of Sugar Yearly
11. New OHSU research helps explain early-onset puberty in females
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Privately owned Contract Development and ... of its current state of the art research, development and manufacturing facility outside ... its manufacturing capacity as well as to support its clients’ growing research and ...
(Date:11/25/2015)... ... November 25, 2015 , ... Many people know of the common symptoms ... hands, and dry skin. But many people who find their cholesterol levels and weight ... of their thyroid, especially if they don’t have any of the other symptoms. , ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... on providing comprehensive solutions involving adult stem cell therapies to patients with chronic ... the “Regenestem” name as a Registered Trademark (RTM). , Organizations are required to ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... treatment, is offering lower prices in an early celebration of the early holiday ... promotional price of $29.95 each (normally $33.95 ea). Black Friday promotional pricing is ...
(Date:11/24/2015)... ... 2015 , ... Eric C. Seidel, DMD and Stephanie DeFilippo, ... revolutionary BIOLASE WaterLase iPlus 2.0™ system. This advanced laser technology uses light energy ... dentist in Gettysburg, PA . From routine visits to cosmetic treatments, laser dentistry ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Frankreich, November 25, 2015 ... bekanntgegeben, dass sie eine Lizenz für das Patent über ... CNRS, UCBL und ENS-Lyon innehaben, an Enyo Pharma vergeben ... FUI AAP8 ins Leben gerufenen und von Edelris gemeinsam ... FXR als ein Behandlungsziel für HBV identifiziert, und es ...
(Date:11/24/2015)... DELHI , November 25, 2015 ... invoked due to repeated failure of IVF cycles. After ... Bhatia was totally dejected and had lost all hopes that she would be ... first Indian miracle child conceived after failure of over ... to abroad (UK) before they decided to take one last attempt ...
(Date:11/24/2015)... 24, 2015  Thanks to a donor with a ... Medical Center,s Sister Diane Grassilli Center for Women,s Health ... San Francisco . ... forward with a gift of $617,320 that allowed the ... with Tomosynthesis and Whole Breast Ultrasound. Tomosynthesis, three-dimensional (3-D) ...
Breaking Medicine Technology: